File:Janssen_COVID-19_vaccine_(2021)_F_(cropped)_2.jpg · Wikimedia Commons · See Wikimedia Commons
Ad26.COV2.S
Sign in to saveAlso known as Ad26COVS1, J7, Janssen vaccine, Jhon, Dutch vaccine, Jcovden
COVID-19 vaccine of Johnson & Johnson
Key facts
- Target
- SARS-CoV-2
- Vaccine type
- Viral vector
- Trade names
- Jcovden
- Other names
- Ad26.COV2.S JNJ-78436735 Ad26COVS1 VAC31518 COVID-19 Vaccine Janssen Johnson & Johnson COVID ‑ 19 vaccine
- Ahfs drugs com
- Multum Consumer Information
- License data
- United States</span>"}]]}'>US DailyMed : Janssen COVID-19 Vaccine
- Pregnancy category
- Australia</span>"}]]}'>AU : B1
- Routes of administration
- Intramuscular
- Atc code
- J07BN02 ( WHO )
- Cas number
- 2541607-46-7
- Drugbank
- DB15857
- Unii
- JT2NS6183B
- Kegg
- D12129
via Wikipedia infobox
Research
714 papers- Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.Immunological reviews · 2022
- Reactive Angioendotheliomatosis Following Ad26.COV2.S Vaccination.Cutis · 2023
- Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.American journal of hematology · 2022
- Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.The American journal of case reports · 2022
- Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination.Annals of hematology · 2022
via PubMed
Wikidata facts
- Instance of
- chemical substance
- Subclass of
- COVID-19 vaccine
- Developer
- Beth Israel Deaconess Medical Center
- Image
- Janssen COVID-19 vaccine (2021) F (cropped).jpg
Show 5 more facts
- vaccine for
- COVID-19
- funder
- Operation Warp Speed
- price
- 8.50
- route of administration
- intramuscular injection
- Commons category
- Janssen COVID-19 vaccine
via Wikidata · CC0
~31 min read
Encyclopedic overview
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.
It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2 virus that causes COVID‑19. The body's immune system responds to this spike protein to produce antibodies. The vaccine requires only one dose and does not need to be stored frozen.
Excerpted from Wikipedia’s “Ad26.COV2.S” article, available under the CC BY-SA 4.0 licence.